STOCK TITAN

Forian (FORA) enters $2.17 per share cash merger with Wygod-led group

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Forian Inc. is the subject of a planned going-private cash merger led by a consortium affiliated with Max Wygod. The reporting persons, including Max C. Wygod, Emily Bushnell and Wygod family trusts, report beneficial ownership stakes such as 12.4% and 11% of Forian’s common stock.

On April 2, 2026, a special purpose vehicle affiliated with Max Wygod and Bravo Merger Sub, Inc. signed a Merger Agreement with Forian. After a tender offer, Forian will merge into the buyer group and become a wholly owned subsidiary, with each outstanding share (other than specified excluded shares) converted into the right to receive $2.17 in cash per share, subject to appraisal rights and tax withholding.

A Wygod family trust committed up to $5,500,000 of equity financing to fund the closing payments. Closing is conditioned on more than 50% of shares being tendered (including existing buyer holdings), the accuracy of certain representations, Forian’s compliance with covenants, absence of a continuing Company Material Adverse Effect, and no blocking court orders.

Positive

  • None.

Negative

  • None.

Insights

Consortium-affiliated vehicle moves to take Forian private at $2.17 per share, backed by a $5.5M equity commitment.

The filing describes a going‑private transaction where an SPV and Merger Sub affiliated with Max Wygod agreed to acquire Forian Inc. via tender offer followed by a short‑form merger. Each eligible share will be converted into $2.17 in cash, indicating a full cash exit for public holders if the deal closes.

The buyer group includes reporting persons holding notable stakes, such as 12.4% and 11% of outstanding shares, calculated against 31,208,751 shares as of March 25, 2026. A Wygod family trust has provided an equity commitment of up to $5,500,000 to fund closing payments, supporting deal financing alongside other resources.

Completion depends on key conditions: tenders plus existing buyer holdings must exceed 50% of outstanding shares, specified representations and covenants must hold, there must be no continuing Company Material Adverse Effect, and no governmental order may block the offer or merger. Subsequent tender offer documents and the Schedule 13E‑3/14D‑9 disclosures will provide further detail on timing and process.

Merger cash consideration $2.17 per share Cash paid for each Forian share at the effective time of the merger
Equity commitment $5,500,000 Maximum equity commitment by a Wygod family trust to fund closing payments
Shares outstanding baseline 31,208,751 shares Forian common shares outstanding as of March 25, 2026, per Form 10-K
Max C. Wygod beneficial ownership 3,859,402 shares (12.4%) Aggregate Forian shares beneficially owned by Max C. Wygod
Emily Bushnell beneficial ownership 3,431,699 shares (11%) Aggregate Forian shares beneficially owned by Emily Bushnell
Administrative Trust holdings 1,040,899 shares (3.3%) Forian shares beneficially owned by Administrative Trust U/ Wygod Family
Family Trust holdings 1,489,576 shares (4.8%) Forian shares beneficially owned by Max Wygod & Emily W Bushnell Co‑TTEE Family Trust
Consortium aggregate holdings reference 20,689,142 shares Shares beneficially owned in aggregate by Consortium members, as referenced in Item 5(b)
Merger Agreement financial
"the SPV, Merger Sub and Forian entered into an Agreement and Plan of Merger"
A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.
Equity Commitment Letter financial
"provided an equity commitment letter, dated April 2, 2026 (the "Equity Commitment Letter")"
A written promise from an investor or group to provide a specified amount of capital for a deal, such as an acquisition or a new financing round. It matters to investors because it shows how likely a transaction is to close and how much fresh money will be available, similar to a down-payment commitment when buying a house: the stronger the promise, the less risk that the deal will fall apart or that existing shareholders will face unexpected dilution.
tender offer statement on Schedule TO regulatory
"the preparation and filing of a tender offer statement on Schedule TO"
A tender offer statement on Schedule TO is a formal regulatory filing that lays out the full terms, timeline, and conditions of a public offer to buy shares from existing shareholders. Think of it as a detailed invitation that explains who is buying, how much they’ll pay, how long the offer runs, and any rules or financing behind it. Investors use it to judge the fairness, likelihood and timing of a buyout and its likely effect on share value and control.
transaction statement on Schedule 13E-3 regulatory
"and a transaction statement on Schedule 13E-3 by Parent, Merger Sub and the Company"
Schedule 14D-9 regulatory
"and a Schedule 14D-9 by the Company in connection with the Transactions"
Schedule 14D-9 is a filing with the U.S. Securities and Exchange Commission in which a company publicly states its response and recommendation to an outside bid to buy its shares (a tender offer). Think of it as the company’s advisory note to shareholders explaining whether to sell, keep, or seek alternatives, and why, with facts and reasoning. Investors rely on it to gauge management’s view of the offer’s fairness and the likely impact on value and strategy.
Company Material Adverse Effect financial
"the non-occurrence of a Company Material Adverse Effect (as defined in the Merger Agreement)"
A company material adverse effect is a significant, harmful change in a company’s business, financial condition, or operations that makes it much less valuable or viable. Investors care because this kind of change can trigger contract protections, delay or cancel deals, and often leads to a sharp re-evaluation of the stock — like discovering a serious health problem that suddenly changes future prospects and insurance coverage.





34630N106

(CUSIP Number)
Creighton Condon
599 Lexington Ave.,
New York, NY, 10022
(212) 848-7628

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/02/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
ITEM 13 Calculated based on 31,208,751 shares of common stock of the Issuer outstanding as of March 25, 2026, as reported on the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
ITEM 13 Calculated based on 31,208,751 shares of common stock of the Issuer outstanding as of March 25, 2026, as reported on the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
ITEM 13 Calculated based on 31,208,751 shares of common stock of the Issuer outstanding as of March 25, 2026, as reported on the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
ITEM 13 Calculated based on 31,208,751 shares of common stock of the Issuer outstanding as of March 25, 2026, as reported on the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025.


SCHEDULE 13D


Max C. Wygod
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod
Date:04/06/2026
Emily Bushnell
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod / Attorney-in-fact for Emily Bushnell
Date:04/06/2026
ADMINISTRATIVE TRUST U/ WYGOD FAMILY RV
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod, Co-Trustee
Date:04/06/2026
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod / Attorney-in-fact for Emily Bushnell, Co-Trustee
Date:04/06/2026
MAX WYGOD & EMILY W BUSHNELL CO-TTEE WYGOD FAMILY REV LT U/T/A
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod, Co-Trustee
Date:04/06/2026
Signature:/s/ Max C. Wygod
Name/Title:Max C. Wygod / Attorney-in-fact for Emily Bushnell, Co-Trustee
Date:04/06/2026

FAQ

What major transaction involving Forian (FORA) is described in this Schedule 13D/A amendment?

The filing describes a planned going‑private transaction for Forian. An SPV and Bravo Merger Sub, affiliated with Max Wygod, agreed to acquire Forian via tender offer followed by a merger under a Merger Agreement signed on April 2, 2026.

What cash consideration will Forian (FORA) shareholders receive in the proposed merger?

Each Forian share issued and outstanding immediately before the merger’s effective time will be converted into the right to receive $2.17 in cash per share. This amount is payable without interest and subject to required tax withholding and any appraisal rights under Maryland law.

Who are the key reporting persons and how much of Forian (FORA) do they beneficially own?

Key reporting persons include Max C. Wygod, Emily Bushnell and Wygod family trusts. Max Wygod reports beneficial ownership of 3,859,402 shares, or 12.4% of the class, while Emily Bushnell reports 3,431,699 shares, or 11%, based on 31,208,751 shares outstanding.

What financing support backs the Forian (FORA) merger transaction?

A Wygod family trust provided an Equity Commitment Letter dated April 2, 2026, committing up to $5,500,000 of equity. This commitment is available solely to fund the closing payments required under the Merger Agreement and is exercisable at or before consummation of the merger.

What are the key conditions required to complete the Forian (FORA) tender offer and merger?

Closing conditions include tenders plus buyer holdings exceeding 50% of outstanding shares, accuracy of specified Forian representations, performance of covenants, no continuing Company Material Adverse Effect, non‑termination of the Merger Agreement, and absence of court orders preventing the offer or merger.

How many Forian (FORA) shares are used to calculate ownership percentages in this filing?

Ownership percentages in the amendment use 31,208,751 Forian common shares outstanding as the denominator. This figure is taken from Forian’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2025, and is stated as of March 25, 2026.